MAXWELL BIOMEDICAL INC

Maxwell Biomedical is a medical device company developing Cardiac Resynchronization Therapy for the Atrium (CRT-A), a first-of-its-kind implantable system designed to restore both sinus rhythm and atrial mechanical function in patients with atrial fibrillation. Their CRT-A system, powered by the Rhythm360 platform, uses spatiotemporal identification of excitable gaps to deliver ultra-low energy stimulation that terminates AF imperceptibly — without tissue destruction. The company targets two major unmet needs: post-surgical AF and AF with heart failure with preserved ejection fraction (HFpEF).